H.C. Wainwright raised the firm’s price target on Delcath Systems to $22 from $20 and keeps a Buy rating on the shares following the Q1 report. The analyst says Hepzato continues to gain traction.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DCTH:
- Delcath Systems Reports First Quarter 2024 Results and Business Highlights
- Delcath Systems initiated with an Overweight at Stephens
- Delcath Systems’ Hepzato Kit in melanoma meets primary Phase 3 endpoint
- DCTH Upcoming Earnings Report: What to Expect?
- Delcath Systems files to sell 1.92M shares of common stock for holders